Archive
549 articles, sorted by publication time.
Epic Bio says its EPICRISPR drug increased muscle mass in type 1 facioscapulohumeral muscular dystrophy; it is a notable early signal, and also a reminder that there is still some distance between gene silencing and clinical benefit.
mRNA-6007 marks Moderna’s first move into the race to generate CAR-T cells inside the body; it promises to simplify cell therapy, but must also answer hard questions about precise delivery, safety switches, and clinical tolerability.
Insilico and SK Biopharmaceuticals are pushing AI drug discovery toward the intersection of neurology and immunology, but beyond the contract ceiling and space-style ambitions, what can truly change patients’ lives remains reproducible, regulatable, and clinically validated biological evidence.
This is not a vaccine already proven to prevent infection, but an earlier form of preparedness: using viral surveillance data and algorithms to assemble immune targets in advance, and testing whether humans can learn to recognize the threat before the next spillover.
This collaboration is not just another piece of news about a major pharmaceutical company chasing the AI boom; it narrows the question to something more concrete: whether models can propose molecules for difficult-to-drug targets that are strong enough to enter experimental and clinical testing.
GLP-1 weight-loss drugs are reshaping the global pharmaceutical market. Brazilian companies see not only sales growth, but also an opportunity to redistribute generics, production capacity, and the burden on public healthcare.
Generative AI can now move candidate molecules into the clinic faster, but from speed to efficacy, and from visions of longevity to regulatory recognition, Insilico faces a much longer process of validation.
The new database brings AI drug discovery’s least visible foundational engineering to the forefront: whether models can propose synthesizable, verifiable molecules often depends on how many reliable reactions they have seen, not only on the algorithms themselves.
The company, which gained recognition by bringing generative AI-designed drugs into clinical trials, is now placing the next phase of its story on the Chinese market and anti-aging medicine. The real test is not only whether algorithms can design molecules, but whether those molecules can hold up in the human body, under regulation, and within payment systems.
The two companies are linking circular RNA expression technology with a non-integrating DNA vector, with the goal not of immediately launching a new therapy, but first of answering whether engineered T cells can be produced in vivo in a more durable and more controllable way.
The numbness and pain caused by chemotherapy often leave traces long after tumors shrink; an AI-designed drug candidate has been cleared to move forward, making “preventing side effects” another clinical testing ground for new drug development.
Insilico and SK Biopharm are extending their collaboration into neuroimmune diseases. The deal has a large potential ceiling, but it looks more like a staged validation exercise: whether AI can generate drug hypotheses for complex pathology that experiments, clinical development, and regulators can support.